AVR Anteris Technologies Global Corp.

Subscribe to $AVR

Anteris Technologies Global Corp.

Subscribe to $AVR

$AVR

Industrial Specialties

Health Care

IPO Year: 2024

Exchange: NASDAQ

Recent Analyst Ratings for Anteris Technologies Global Corp.

Date	Price Target	Rating	Analyst
1/8/2025	$20.00	Buy	Lake Street
1/7/2025	$15.00	Buy	TD Cowen
1/7/2025	$9.00	Overweight	Cantor Fitzgerald
1/7/2025	$22.00	Overweight	Barclays

See more ratings

Anteris Technologies Global Corp. Press Releases

Fastest customizable press release news feed in the world

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors
MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o
6/9/25 10:52:06 PM ET
$AVR
$LMAT
Industrial Specialties
Health Care
Medical/Dental Instruments
Anteris Announces Results for the First Quarter of 2025
MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption ("IDE") for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial"), submitted to the FDA during the First QuarterScale up for commencement of the PARADIGM Trial ongoing – including expanding the Clinical S
5/13/25 5:45:28 PM ET
$AVR
Industrial Specialties
Health Care
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR® THV,
3/31/25 7:15:40 AM ET
$AVR
Industrial Specialties
Health Care
Anteris Reports One-Year Patient Outcomes for DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia, March 21, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced one-year results for patients treated with its proprietary, balloon expandable, DurAVR® Transcatheter Heart Valve (THV) System. Rishi Puri, M.D. PhD presented the data at a late breaking clinical trial session at Sydney Valves on Friday 21 March 2025, 10:30am (AEST), titled: "Pioneering a New Class of Biomimetic TAVR with Sustained 1-Year Performance." One-year Results
3/21/25 7:30:00 AM ET
$AVR
Industrial Specialties
Health Care
Anteris Reports 2024 Financial Results and Provides Corporate Update
EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2024, and provided a corporate update. 2024 Full Year Highlights & Recent Developments Achieved a successful U.S. Initial Public Offering ("IPO") onto Nasdaq raising $88.8m (AUD $139.3m) before costs and commissions and excluding the underwriters option, which completed the Company's re-domiciliation to the United
3/12/25 8:33:06 PM ET
$AVR
Industrial Specialties
Health Care
Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays
MINNEAPOLIS and BRISBANE, Australia, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Anteris® Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a structural heart company developing DurAVR® THV, a first-in-class, biomimetic, balloon expandable heart valve, is pleased to advise that Chief Executive Officer, Wayne Paterson will be presenting at both the 45th Annual TD Cowen Healthcare Conference, and the Barclays 27th Annual Global Healthcare Conference. The details of each conference and how to access them are as follows: TD Cowen 45th Annual Healthcare ConferenceDate: Wednesday, March 5th, 2025 (US time)Format: Fireside chat with analyst, Joshua Jennin
2/28/25 8:00:00 AM ET
$AVR
Industrial Specialties
Health Care
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
Anteris Technologies Global Corp. ("ATGC" or "Anteris") is pleased to announce the closing of its initial public offering of 14,800,000 shares of its common stock (the "Common Stock") in the U.S. at a price of $6.00 per share (the "Offering"). An additional 2,220,000 shares of Common Stock are issuable pursuant to the underwriters' option to purchase additional shares of Common Stock from ATGC (the "Green Shoe"), if exercised in full. ATGC's Common Stock is listed on the Nasdaq Global Market ("NASDAQ") from December 13, 2024, trading under the ticker symbol "AVR." The aggregate gross proceeds to ATGC from the Offering were approximately $88.8 million ($A 138.4 million) prior to underwriti
12/16/24 7:49:00 PM ET
$AVR
Industrial Specialties
Health Care

Anteris Technologies Global Corp.

Recent Analyst Ratings for Anteris Technologies Global Corp.

Anteris Technologies Global Corp.

Recent Analyst Ratings for Anteris Technologies Global Corp.

Anteris Technologies Global Corp. SEC Filings

Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update

SEC Form 10-Q filed by Anteris Technologies Global Corp.

Amendment: SEC Form 10-K/A filed by Anteris Technologies Global Corp.

SEC Form SCHEDULE 13G filed by Anteris Technologies Global Corp.

Anteris Technologies Global Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Anteris Technologies Global Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by Anteris Technologies Global Corp.

Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update

SEC Form SCHEDULE 13G filed by Anteris Technologies Global Corp.

SEC Form SCHEDULE 13G filed by Anteris Technologies Global Corp.

Anteris Technologies Global Corp. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

Barclays initiated coverage on Anteris Technologies Global Corp. with a new price target

Anteris Technologies Global Corp. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 3 filed by new insider Moss Gregory S.

SEC Form 3 filed by new insider Roberts David B

Amendment: Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

Amendment: Chief Executive Officer Paterson Wayne exercised 233,000 shares at a strike of $7.13 and covered exercise/tax liability with 220,393 shares (SEC Form 4)

Amendment: Director Denaro Stephen exercised 16,500 shares at a strike of $7.13 (SEC Form 4)

Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

Chief Executive Officer Paterson Wayne exercised 233,000 shares at a strike of $7.13 and covered exercise/tax liability with 220,393 shares (SEC Form 4)

Director Denaro Stephen exercised 16,500 shares at a strike of $7.13 (SEC Form 4)

SEC Form 3 filed by new insider L1 Capital Pty Ltd

Director Denaro Stephen was granted 7,222 shares (SEC Form 4)

Anteris Technologies Global Corp. Press Releases

Fastest customizable press release news feed in the world

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

Anteris Announces Results for the First Quarter of 2025

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

Anteris Reports 2024 Financial Results and Provides Corporate Update

Anteris to Present at Healthcare Investor Conferences - TD Cowen and Barclays

Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering

Anteris Technologies Global Corp. Leadership Updates

Live Leadership Updates

Anteris Appoints David Roberts and Gregory Moss to its Board of Directors